Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8
Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.
PhaseBio Pharmaceuticals Q2 EPS $(0.34) Up From $(0.60) YoY, Sales $208.00K Down From $10.34M YoY
PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported quarterly losses of $(0.34) per share. This is a 43.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported $208.00
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion.
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers
Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers
Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale.
Coinbase, Moderna And 56 Biggest Movers From Yesterday
Gainers
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 75.2% to close at $2.19 after the company announced it has developed a non-invasive blood sensor designated to alert real-time change in patients' clinical condition.